Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics is a biotechnology company developing investigational medicines for inherited and other serious disorders of blood coagulation. Its therapeutic research focuses on treatments intended to address conditions associated with abnormal bleeding and clot formation. The company conducts development activities spanning biological medicines and clinical research, with operations in the United States and Denmark. Hemab operates as a publicly listed issuer and makes corporate disclosures available through its investor relations website.
Company at a glance
Corporate information
- Company entity
- Hemab Therapeutics Holdings, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://hemab.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Global Select Market: COAG
antibody therapeutics · hematology
coagulation disorders · rare diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Hemab Therapeutics is a biotechnology company developing investigational medicines for inherited and other serious disorders of blood coagulation. Its therapeutic research focuses on treatments intended to address conditions associated with abnormal bleeding and clot formation. The company conducts development activities spanning biological medicines and clinical research, with operations in the United States and Denmark. Hemab operates as a publicly listed issuer and makes corporate disclosures available through its investor relations website.
Business, technology & evidence
- SecuritiesNasdaq Global Select Market: COAG
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Hemab Therapeutics Holdings, Inc. ↗Hemab Therapeutics Holdings, Inc. ·
- Official issuer and R&D disclosure · Hemab Therapeutics Holdings, Inc. ↗Hemab Therapeutics Holdings, Inc. ·
- Official issuer and R&D disclosure · Hemab Therapeutics Holdings, Inc. ↗Hemab Therapeutics Holdings, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.